C07K 14/705
Receptors
Official title: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
C07K14/705 (Receptors) appears on 18,452 US grants and 30,741 published applications in this corpus.
Search patents in C07K- Granted patents
- 18,452
- Published applications
- 30,741
- Assignees
- 6,591
- Inventors
- 40,201
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 4 | 0 |
| 1986 | 2 | 0 |
| 1987 | 4 | 0 |
| 1988 | 5 | 0 |
| 1989 | 16 | 0 |
| 1990 | 23 | 0 |
| 1991 | 24 | 0 |
| 1992 | 54 | 0 |
| 1993 | 112 | 0 |
| 1994 | 112 | 0 |
| 1995 | 154 | 0 |
| 1996 | 242 | 0 |
| 1997 | 402 | 0 |
| 1998 | 595 | 0 |
| 1999 | 617 | 0 |
| 2000 | 525 | 0 |
| 2001 | 535 | 96 |
| 2002 | 531 | 1140 |
| 2003 | 474 | 3080 |
| 2004 | 419 | 1211 |
| 2005 | 385 | 1108 |
| 2006 | 628 | 905 |
| 2007 | 689 | 783 |
| 2008 | 622 | 687 |
| 2009 | 483 | 836 |
| 2010 | 518 | 729 |
| 2011 | 466 | 698 |
| 2012 | 467 | 580 |
| 2013 | 397 | 625 |
| 2014 | 402 | 671 |
| 2015 | 411 | 703 |
| 2016 | 460 | 821 |
| 2017 | 487 | 933 |
| 2018 | 543 | 1127 |
| 2019 | 713 | 1418 |
| 2020 | 821 | 1627 |
| 2021 | 861 | 1890 |
| 2022 | 879 | 2062 |
| 2023 | 802 | 1904 |
| 2024 | 957 | 2076 |
| 2025 | 962 | 1756 |
| 2026 | 646 | 1275 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07K 14/70503Immunoglobulin superfamily6,238
- C07K 14/715For cytokines2,377
- C07K 14/71For growth factors1,948
- C07K 14/70578Ngf-receptor/tnf-receptor superfamily1,552
- C07K 14/72For hormones1,427
- C07K 14/70596Molecules with a "cd"-designation not provided for elsewhere1,186
- C07K 14/70575Ngf/tnf-superfamily690
- C07K 14/70571For neuromediators645
Recent patents
- Methods of preparation of pan TLR antagonistic liposomal-LNP formulations and uses thereof6 Oct 2026US 12,751,920 B2Celestial Therapeutics, Inc.
- Compositions, methods and kits for treating complement related disorders6 Oct 2026US 12,751,993 B2Trustees of Tufts College
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Application of CCR5hi Innate Immune Memory Cells in Preparation of Immunotherapeutic Drug for Treating Sepsis8 Oct 2026US 2026/0306538 A1Children's Hospital of Soochow University
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Cd28h domain-containing chimeric antigen receptors and methods of use8 Oct 2026US 2026/0306544 A1The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- Timp3-derived teipp neoantigens and uses thereof8 Oct 2026US 2026/0306599 A1
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Neural regeneration peptides and methods for their use in treatment of brain damage1,465US 7,563,862 B2Neuren Pharmaceuticals Limited · 2009